The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
42 | 40 | 54 | 89 |
Growth
|
50 | 84 | 75 | 49 |
Safety
|
37 | 33 | 53 | 24 |
Sentiment
|
25 | 40 | 86 | 20 |
|
12 | 47 | 92 | 33 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
32 | 60 | 22 | 57 |
Opinions Change
|
50 | 50 | 100 | 50 |
Pro Holdings
|
n/a | 1 | 78 | 24 |
Market Pulse
|
64 | 69 | 70 | 25 |
Sentiment
|
25 | 40 | 86 | 20 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
42 | 40 | 54 | 89 |
Growth
|
50 | 84 | 75 | 49 |
|
37 | 33 | 53 | 24 |
Combined
|
31 | 55 | 71 | 53 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
86 | 86 | 86 | 24 |
Price vs. Earnings (P/E)
|
80 | 82 | 87 | 93 |
Price vs. Book (P/B)
|
79 | 59 | 75 | 95 |
Dividend Yield
|
1 | 1 | 1 | 100 |
Value
|
42 | 40 | 54 | 89 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
37 | 71 | 80 | 93 |
Profit Growth
|
30 | 72 | 4 | 1 |
Capital Growth
|
40 | 56 | 50 | 71 |
Stock Returns
|
94 | 70 | 99 | 31 |
Growth
|
50 | 84 | 75 | 49 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
67 | 59 | 65 | 22 |
Refinancing
|
54 | 58 | 83 | 77 |
Liquidity
|
4 | 4 | 8 | 8 |
|
37 | 33 | 53 | 24 |
Discover high‑ranked alternatives to Mayne Pharma and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.